Cloudbreak Pharma (HKSE:02592) Notes Receivable: HK$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02592 Cloudbreak Pharma Inc HKSE:02592
11 GF Score
Price HK$1.22
! 2 Warning Signs
View Full Analysis

What is Cloudbreak Pharma Notes Receivable?

Cloudbreak Pharma HKSE:02592 +0.83% 11 Notes Receivable is HK$0.00 Mil as of Dec. 2025. GuruFocus rates HKSE:02592 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Cloudbreak Pharma's Notes Receivable for the quarter that ended in Dec. 2025 was HK$0.00 Mil.

Cloudbreak Pharma Notes Receivable Related Terms

Cloudbreak Pharma Notes Receivable Historical Data

* Premium members only.

The historical data trend for Cloudbreak Pharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cloudbreak Pharma Notes Receivable Chart

Cloudbreak Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00

Cloudbreak Pharma Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
HKSE:02592
11GF Score
Cloudbreak Pharma Inc HKSE:02592
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cloudbreak Pharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of HK$0.00 Mil mean?
Cloudbreak Pharma (HKSE:02592) has a Notes Receivable of HK$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Cloudbreak Pharma and its competitors.
Is Cloudbreak Pharma's Notes Receivable too high?
Cloudbreak Pharma's current Notes Receivable is HK$0.00 Mil. Overall, Cloudbreak Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cloudbreak Pharma's Notes Receivable compare to VRTX and REGN?
Cloudbreak Pharma's Notes Receivable of HK$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Cloudbreak Pharma and its competitors. Cloudbreak Pharma's current Notes Receivable is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cloudbreak Pharma stock overvalued right now?
Cloudbreak Pharma (HKSE:02592) has a current Notes Receivable of HK$0.00 Mil. The current Notes Receivable is HK$0.00 Mil. Cloudbreak Pharma's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Cloudbreak Pharma (HKSE:02592), the current Notes Receivable is HK$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cloudbreak Pharma Business Description

Address 8921 Research Drive, Irvine, CA, USA, 92618
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
11GF Score

Get the complete analysis for HKSE:02592

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.22
Price